# US 2002/0165156 A1 · BAFF receptor (BCMA), an immunoregulatory agent

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2002/0165156 A1
- Document ID: US20020165156A1
- Status: Published application
- Kind: A1
- Application number: 10/077,438
- Filed: 2002-02-15
- Published: 2002-11-07
- Earliest claimed: 1999-08-17
- Assignees: Biogen Idcc MA Inc.; Apoxis SA
- Inventors: Jeffrey Browning; Christine Ambrose; Fabienne MacKay; Jurg Tschopp; Pascal Schneider; Jeffrey Thompson
- Web page: https://patentgrep.com/patent/US20020165156A1

## CPC

- C07K 14/7151: {for tumor necrosis factor [TNF], for lymphotoxin [LT]}
- A61K 38/17: from animals; from humans {(enzyme inhibitors A61K38/005)}
- A61K 39/395: Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K 47/68: the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 7/06: Antianaemics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 13/12: of the kidneys
- A61P 17/00: Drugs for dermatological disorders
- A61P 21/04: for myasthenia gravis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/18: for HIV
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/70575: {NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154 (NGF C07K14/48, TNF C07K14/525)}
- C07K 16/241: {Tumor Necrosis Factors}
- A61K 38/1793: {for cytokines; for lymphokines; for interferons}
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 2039/505: {comprising antibodies}
- C07K 2319/00: Fusion polypeptide
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A novel receptor in the TNF family is provided: BAFF-R. Chimeric molecules and antibodies to BAFF-R and methods of use thereof are also provided.

## Claims

### Claim 1

A method of inhibiting B-cell growth in an animal comprising the step of administering a therapeutically effective amount of a composition selected from the group consisting of:
(a) a BAFF-R polypeptide or fragment thereof;
(b) a chimeric molecule comprising a BAFF-R polypeptide or fragment thereof fused to a heterologous amino acid sequence; and
(c) an anti-BAFF-R antibody homolog.

### Claim 2

A method of inhibiting immunoglobulin production in an animal comprising the step of administering a therapeutically effective amount of a composition selected from the group consisting of:
(a) a BAFF-R polypeptide or fragment thereof;
(b) a chimeric molecule comprising a BAFF-R polypeptide or fragment thereof fused to a heterologous amino acid sequence; and
(c) an anti-BAFF-R antibody homolog.

### Claim 3

A method of inhibiting dendritic cell-induced B-cell growth and maturation in an animal comprising the step of administering a therapeutically effective amount of a composition selected from the group consisting of:
(a) a BAFF-R polypeptide or fragment thereof;
(b) a chimeric molecule comprising a BAFF-R polypeptide or fragment thereof fused to a heterologous amino acid sequence; and
(c) an anti-BAFF-R antibody homolog.

### Claim 4

A method of treatment of an autoimmune disease comprising the step of administering a therapeutically effective amount of a composition selected from the group consisting of:
(a) a BAFF-R polypeptide or fragment thereof;
(b) a chimeric molecule comprising a BAFF-R polypeptide or fragment thereof fused to a heterologous amino acid sequence; and
(c) an anti-BAFF-R antibody homolog.

### Claim 5

A method of treating hypertension in an animal comprising the step of administering a therapeutically effective amount of a B-cell growth inhibitor selected from the group consisting of:
(a) a BAFF-R polypeptide or fragment thereof;
(b) a chimeric molecule comprising a BAFF-R polypeptide or fragment thereof fused to a heterologous amino acid sequence; and
(c) an anti-BAFF-R antibody homolog.

### Claim 6

A method of treating renal disorders in an animal comprising the step of administering a therapeutically effective amount of a B-cell growth inhibitor selected from the group consisting of:
(a) a BAFF-R polypeptide or fragment thereof;
(b) a chimeric molecule comprising a BAFF-R polypeptide or fragment thereof fused to a heterologous amino acid sequence; and
(c) an anti-BAFF-R antibody homolog.

### Claim 7

A method of treating B-cell lympho-proliferate disorders comprising the step of administering a therapeutically effective amount of a B-cell growth inhibitor selected from the group consisting of:
(a) a BAFF-R polypeptide or fragment thereof;
(b) a chimeric molecule comprising a BAFF-R polypeptide or fragment thereof fused to a heterologous amino acid sequence; and
(c) an anti-BAFF-R antibody homolog.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

A method according to claims 1 to 7, wherein the BAFF-R polypeptide is soluble.

### Claim 9 (depends on 8)

The method according to claim 8, wherein the soluble BAFF-R polypeptide comprises a BAFF-R extracellular domain.

### Claim 10 (depends on 9)

The method of claim 9 wherein the BAFF-R extracellular domain is fused to an immunoglobulin.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7)

A method according to claims 1 to 7, wherein the BAFF-R polypeptide is selected from the group consisting of:
a) an isolated native sequence BAFF-R polypeptide comprising amino acid residues 1 to 184 of SEQ ID NO:1 or a fragment thereof;
b) an isolated BAFF-R polypeptide having at least 80% amino acid sequence identity with native sequence BAFF-R polypeptide comprising amino acid residues 1 to 184 of SEQ ID NO: 1 or a fragment thereof;
c) an isolated BAFF-R polypeptide having at least 90% amino acid sequence identity with native sequence BAFF-R polypeptide comprising amino acid residues 1 to 184 of SEQ ID NO: 1 or a fragment thereof;
d) an isolated BAFF-R polypeptide comprising amino acid residues 1 to 51 of SEQ ID NO: 1 or a fragment thereof; and
e) an isolated BAFF-R polypeptide comprising amino acid residues 8 to 41 of SEQ ID NO: 1 or a fragment thereof.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7)

A method according to claims 1 to 7, wherein the anti-BAFF-R antibody homolog is a monoclonal antibody.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7)

A method according to claims 1 to 7, wherein the anti-BAFF-R antibody homolog comprises BCMA-IgG.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7)

A method according to claims 1 to 7, wherein the animal is a mammal.

### Claim 15 (depends on 14)

The method according to claim 14, wherein the mammal is human.

### Claim 16

A method of treating, suppressing or altering an immune response involving a signaling pathway between a BAFF-R and BAFF comprising the step of administering an effective amount of an agent capable of interfering with the association between the BAFF-R and BAFF.

### Claim 17

A method of inhibiting inflammation comprising the step of administering a therapeutically effective amount of an antibody specific for a BAFF-R or an active fragment thereof.

### Claim 18

A method of inhibiting inflammation comprising the step of administering a therapeutically effective amount of an antibody specific for a BAFF-R or an epitope thereof.

### Claim 19

A pharmaceutical composition comprising a therapeutically effective amount of an isolated BAFF-R polypeptide or a fragment thereof and a pharmaceutically acceptable carrier.

### Claim 20 (depends on 19)

The pharmaceutical composition of claim 19 wherein the isolated BAFF-R polypeptide is selected from the group consisting of:
a) an isolated native sequence BAFF-R polypeptide comprising amino acid residues 1 to 184 of SEQ ID NO:1 or a fragment thereof;
b) an isolated BAFF-R polypeptide having at least 80% amino acid sequence identity with native sequence BAFF-R polypeptide comprising amino acid residues 1 to 184 of SEQ ID NO: 1 or a fragment thereof;
c) an isolated BAFF-R polypeptide having at least 90% amino acid sequence identity with native sequence BAFF-R polypeptide comprising amino acid residues 1 to 184 of SEQ ID NO: 1 or a fragment thereof;
d) an isolated BAFF-R polypeptide comprising amino acid residues 1 to 51 of SEQ ID NO: 1 or a fragment thereof; and
e) an isolated BAFF-R polypeptide comprising amino acid residues 8 to 41 of SEQ ID NO: 1 or a fragment thereof.

### Claim 21 (depends on 19)

The pharmaceutical composition of claim 19 wherein the BAFF-R polypeptide fragment comprises a BAFF-R extracellular domain fused to an immunoglobulin.
